Literature DB >> 12171927

Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization.

Michelle A Poirier1, Huilin Li, Jed Macosko, Shuowei Cai, Mario Amzel, Christopher A Ross.   

Abstract

The pathology of Huntington's disease is characterized by neuronal degeneration and inclusions containing N-terminal fragments of mutant huntingtin (htt). To study htt aggregation, we examined purified htt fragments in vitro, finding globular and protofibrillar intermediates participating in the genesis of mature fibrils. These intermediates were high in beta-structure. Furthermore, Congo Red, a dye that stains amyloid fibrils, prevented the assembly of mutant htt into mature fibrils, but not the formation of protofibrils. Other proteins capable of forming ordered aggregates, such as amyloid beta and alpha-synuclein, form similar intermediates, suggesting that the mechanisms of mutant htt aggregation and possibly htt toxicity may overlap with other neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12171927     DOI: 10.1074/jbc.M205809200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  108 in total

1.  Protofilament Structure and Supramolecular Polymorphism of Aggregated Mutant Huntingtin Exon 1.

Authors:  Jennifer C Boatz; Talia Piretra; Alessia Lasorsa; Irina Matlahov; James F Conway; Patrick C A van der Wel
Journal:  J Mol Biol       Date:  2020-06-27       Impact factor: 5.469

Review 2.  Intercellular (mis)communication in neurodegenerative disease.

Authors:  Gwenn A Garden; Albert R La Spada
Journal:  Neuron       Date:  2012-03-08       Impact factor: 17.173

3.  Polyglutamine fibrillogenesis: the pathway unfolds.

Authors:  Christopher A Ross; Michelle A Poirier; Erich E Wanker; Mario Amzel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-30       Impact factor: 11.205

4.  Human cytomegalovirus UL97 kinase prevents the deposition of mutant protein aggregates in cellular models of Huntington's disease and ataxia.

Authors:  Cristy Tower; Lianwu Fu; Rachel Gill; Mark Prichard; Mathieu Lesort; Elizabeth Sztul
Journal:  Neurobiol Dis       Date:  2010-08-20       Impact factor: 5.996

5.  Chaperone-like N-methyl peptide inhibitors of polyglutamine aggregation.

Authors:  Jennifer D Lanning; Andrew J Hawk; Johnmark Derryberry; Stephen C Meredith
Journal:  Biochemistry       Date:  2010-08-24       Impact factor: 3.162

Review 6.  Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence.

Authors:  Ronald Wetzel
Journal:  J Mol Biol       Date:  2012-01-27       Impact factor: 5.469

7.  Disease-associated polyglutamine stretches in monomeric huntingtin adopt a compact structure.

Authors:  Clare Peters-Libeu; Jason Miller; Earl Rutenber; Yvonne Newhouse; Preethi Krishnan; Kenneth Cheung; Danny Hatters; Elizabeth Brooks; Kartika Widjaja; Tina Tran; Siddhartha Mitra; Montserrat Arrasate; Luis A Mosquera; Dean Taylor; Karl H Weisgraber; Steven Finkbeiner
Journal:  J Mol Biol       Date:  2012-01-28       Impact factor: 5.469

8.  Studying polyglutamine aggregation in Caenorhabditis elegans using an analytical ultracentrifuge equipped with fluorescence detection.

Authors:  Bashkim Kokona; Carrie A May; Nicole R Cunningham; Lynn Richmond; F Jay Garcia; Julia C Durante; Kathleen M Ulrich; Christine M Roberts; Christopher D Link; Walter F Stafford; Thomas M Laue; Robert Fairman
Journal:  Protein Sci       Date:  2015-12-21       Impact factor: 6.725

9.  Architecture of polyglutamine-containing fibrils from time-resolved fluorescence decay.

Authors:  Christoph Röthlein; Markus S Miettinen; Tejas Borwankar; Jörg Bürger; Thorsten Mielke; Michael U Kumke; Zoya Ignatova
Journal:  J Biol Chem       Date:  2014-08-04       Impact factor: 5.157

Review 10.  A novel therapeutic strategy for polyglutamine diseases by stabilizing aggregation-prone proteins with small molecules.

Authors:  Motomasa Tanaka; Yoko Machida; Nobuyuki Nukina
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.